Raymond James analyst Sean McCutcheon downgraded Compass Therapeutics (CMPX) to Market Perform from Outperform with no price target after Compass disclosed survival outcomes from COMPANION-002, the Phase 3 trial of tovecimig in combination with paclitaxel for the treatment of second line biliary tract cancer. The dataset “sits within the true bear scenario from our preview of the readout,” says the analyst, whose confidence in the approval and a potential commercialization of tovecimig in 2L BTC is reduced.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics price target lowered to $6 from $12 at Stifel
- Compass Therapeutics selloff ‘an over-reaction,’ says Jefferies
- Leerink says Compass data supports path forward for tovecimig in 2L BTC
- Midday Fly By: Verizon reports ‘beat and raise,’ Shell to acquire ARC
- Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged